Prognostic biomarker CCR6 and its correlation with immune infiltration in cutaneous melanoma

Frontiers in Oncology

Oncology

Yang Huang¹  Hang Ji²  Liang Gang²  Damao Dai³  Julong Hu⁴  Yeltai Nurzat⁴  Zaihuan Lin⁴  Feiyu Zhang⁴  Xiaowen Zhang⁵ 

[1] Department of Operating Room, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China;Department of Plastic Surgery, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China;Department of Plastic and Cosmetic Surgery, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China;State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China;State Key Laboratory of Respiratory Disease, Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China;Department of Allergy and Clinical Immunology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;Department of Cancer, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;

关键词: cutaneous melanoma;    CCR6;    TCGA database;    prognosis;    biomarker;   

DOI  :  10.3389/fonc.2023.1162406

 received in 2023-02-09, accepted in 2023-04-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundCutaneous melanoma (CM) is an aggressive type of skin cancer. Even after standard treatment, the recurrence and malignant progression of CM were almost inevitable. The overall survival (OS) of patients with CM varied widely, making it critical for prognostic prediction. Based on the correlation between CCR6 and melanoma incidence, we aimed to investigate the prognostic role of CCR6 and its relationship with immune infiltration in CM.MethodsWe obtained RNA sequencing data from The Cancer Genome Atlas (TCGA) to analyze the CM expression. Functional enrichment analyses, immune infiltration analyses, immune checkpoint analyses, and clinicopathology analyses were performed. Univariate and multivariate Cox regression analyses were used to identify independent prognostic factors. A nomogram model had been developed. Kaplan–Meier survival analysis and log-rank test were used to estimate the relationship between OS and CCR6 expression.ResultsCCR6 was significantly upregulated in CM. Functional enrichment analyses revealed that CCR6 was correlated with immune response. Most immune cells and immune checkpoints were positively correlated with CCR6 expression. Kaplan–Meier analyses showed that high CCR6 expression was associated with a good outcome in CM and its subtypes. Cox regression showed that CCR6 was an independent prognostic factor in patients with CM (HR = 0.550, 95% CI = 0.332–0.912, p<0.05).ConclusionsCCR6 is considered to be a new prognostic biomarker for patients with CM, and our study provides a potential therapeutic target for CM treatment.

【 授权许可】

Unknown   
Copyright © 2023 Nurzat, Dai, Hu, Zhang, Lin, Huang, Gang, Ji and Zhang